Brief Summary

The primary objective of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL).  ONO-4685 is a bispecific antibody that can bind to two target proteins: PD-1 on cancer cells and CD3 on T-cells which may induce the anti-cancer activity of T-cells. Study participants will receive ONO-4685 by intravenous (IV) infusion. Response to the study drug will be measured at regular timepoints throughout the study using standard PTCL and CTCL assessment tools. 

Website: https://www.clinicaltrials.gov/study/NCT05079282

Sponsor: Ono Pharmaceutical Co. Ltd

Contacts and Locations: To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05079282